Rallybio Company Profile, Contacts & Intelligence

Rallybio Overview

Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of complement dysregulation, hematology, and metabolic disorders. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation. Rallybio also has two programs in preclinical development, including REV102, an ENPP1 inhibitor for the treatment of patients with hypophosphatasia (HPP), and RLYB332, a long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Rallybio is headquartered in New Haven, Connecticut.

Headquarters

234 Church Street

Website

rallybio.com

Industry

Biotechnology Research

Founded

2018

Stock Symbol

RLYB

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

Phone Number

Available in AeroLeads

Company Email

Available in AeroLeads

Rallybio Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Rallybio People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Rallybio Workforce Composition

Seniority breakdown across 18 visible profiles.

Compare Similar Companies to Rallybio

Explore companies in related markets and compare their industry and employee estimates.